Sudha Rao

QIMR Berghofer Medical Research Institute — Australia

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index4.8kcitations142works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epigenetics and DNA Methylation(36), Immune Cell Function and Interaction(17), T-cell and B-cell Immunology(15), Cancer Immunotherapy and Biomarkers(13), Genomics and Chromatin Dynamics(12)

Publications142 total

Abstract PS5-08-04: A phase 1b, multi-centre, open-label, randomized study to evaluate the safety, tolerability, and clinical activity of combining paxalisib with olaparib or pembrolizumab/chemotherapy in patients with advanced breast cancer
Clinical Cancer Research·2026
Abstract PS2-10-02: Liquid Biopsy Tracking of PI3K-mTOR Residual Disease Signatures in Metastatic Breast Cancer
Clinical Cancer Research·2026
Supplementary Figure 1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure 6 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure 4 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Data from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure 3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure 5 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Methods from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure 7 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025Open Access
Echoes in AI: Quantifying lack of plot diversity in LLM outputs
Proceedings of the National Academy of Sciences·2025· 4 citedOpen Access
268P Activating immune engagement against pancreatic ductal adenocarcinoma (PDAC): Effect of LSTA-1 and durvalumab on tumour-infiltrating lymphocytes (TILs)
Annals of Oncology·2025
297P Changes in the microbiome during treatment with chemo-immunotherapy in patients diagnosed with pancreatic ductal adenocarcinoma (PDAC): A prospective study
Annals of Oncology·2025Open Access
Abstract P3-06-27: Immunotherapy and PI3K/mTOR inhibition combination to mediate metastasis and immunotherapy resistance in triple-negative breast cancer
Clinical Cancer Research·2025
Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Molecular Cancer Therapeutics·2025· 3 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Robert McCuaig(14), Kristine Hardy(11), Jasmine Li(10), Elissa L. Sutcliffe(8), Fan Wu(8), Jane E. Dahlstrom(8), Stephen T. Turner(7), Anjum Zafar(7), Wen Juan Tu(7), Christopher R. Parish(6), M Shannon(6), Christopher R. Sutton(6), Desmond Yip(6), Abel Tan(6), Brendan E. Russ(5), Jenny C. Dunn(5), Laeeq Malik(5), Pek Siew Lim(5), Peter J. Milburn(5), Nabila Seddiki(5)